Search results
Results from the WOW.Com Content Network
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $3.12, marking a -0.32% move from the previous day.
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $2.84, moving -0.35% from the previous trading session.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
For premium support please call: 800-290-4726 more ways to reach us
The Inovio technology is based on inserting engineered DNA into cells, where it becomes transcribed into mRNA and translated into proteins. The proteins encoded by the DNA elicit immune response to antigens from cancers and viruses, by stimulating the production of T cells and antibodies that aid recovery. [6]
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. [2] Twist was founded in 2013 by Emily Leproust , Bill Banyai, and Bill Peck.
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Its stock is a tracking stock of Applera, along with the tracking stock of Applera's larger Applied Biosystems Group business unit. Celera sequenced the human genome at a fraction of the cost of the publicly funded Human Genome Project (HGP), using about $300 million of private funding versus approximately $3 billion of taxpayer dollars.